Alloantigen pretreatment induces a down-regulation of thein vivo subsequent development of cytotoxic T lymphocytes directed against linked alloantigens

1989 ◽  
Vol 19 (8) ◽  
pp. 1365-1371 ◽  
Author(s):  
Marie-Paule Schutze ◽  
Pierre Langlade-Demoyen ◽  
Grzegorz Przewlocki ◽  
Claude Leclerc
2016 ◽  
Vol 56 ◽  
pp. 180-188 ◽  
Author(s):  
Mónica Pascual-García ◽  
Cristina Bértolo ◽  
Juan C. Nieto ◽  
Neus Serrat ◽  
Íñigo Espinosa ◽  
...  

2011 ◽  
Vol 51 (1) ◽  
pp. 71-79 ◽  
Author(s):  
Chao-Hsu Li ◽  
Wen-Hong Kuo ◽  
Wen-Chun Chang ◽  
Su-Cheng Huang ◽  
King-Jen Chang ◽  
...  

2020 ◽  
Vol 117 (38) ◽  
pp. 23835-23846
Author(s):  
Mark M. Painter ◽  
Gretchen E. Zimmerman ◽  
Madeline S. Merlino ◽  
Andrew W. Robertson ◽  
Valeri H. Terry ◽  
...  

Nef is an HIV-encoded accessory protein that enhances pathogenicity by down-regulating major histocompatibility class I (MHC-I) expression to evade killing by cytotoxic T lymphocytes (CTLs). A potent Nef inhibitor that restores MHC-I is needed to promote immune-mediated clearance of HIV-infected cells. We discovered that the plecomacrolide family of natural products restored MHC-I to the surface of Nef-expressing primary cells with variable potency. Concanamycin A (CMA) counteracted Nef at subnanomolar concentrations that did not interfere with lysosomal acidification or degradation and were nontoxic in primary cell cultures. CMA specifically reversed Nef-mediated down-regulation of MHC-I, but not CD4, and cells treated with CMA showed reduced formation of the Nef:MHC-I:AP-1 complex required for MHC-I down-regulation. CMA restored expression of diverse allotypes of MHC-I in Nef-expressing cells and inhibited Nef alleles from divergent clades of HIV and simian immunodeficiency virus, including from primary patient isolates. Lastly, we found that restoration of MHC-I in HIV-infected cells was accompanied by enhanced CTL-mediated clearance of infected cells comparable to genetic deletion of Nef. Thus, we propose CMA as a lead compound for therapeutic inhibition of Nef to enhance immune-mediated clearance of HIV-infected cells.


2009 ◽  
Vol 106 (26) ◽  
pp. 10746-10751 ◽  
Author(s):  
R. Ueda ◽  
G. Kohanbash ◽  
K. Sasaki ◽  
M. Fujita ◽  
X. Zhu ◽  
...  

Blood ◽  
2012 ◽  
Vol 120 (1) ◽  
pp. 100-111 ◽  
Author(s):  
Diana Y. Chen ◽  
Arumugam Balamurugan ◽  
Hwee L. Ng ◽  
William G. Cumberland ◽  
Otto O. Yang

AbstractThe impact of HIV-1 Nef-mediated HLA-I down-regulation on CD8+ cytotoxic T lymphocytes (CTLs) varies by epitope, but the determining factors have not been elucidated. In the present study, we investigated the impact of Nef on the antiviral efficiency of HIV-1–specific CTLs targeting 17 different epitopes to define properties that determine susceptibility to Nef. The impact of Nef was not correlated with the presenting HLA-I type or functional avidity of CTLs, but instead was related directly to the kinetics of infected cell clearance. Whereas Gag-specific CTLs generally were less susceptible to Nef than those targeting other proteins, this was determined by the ability to eliminate infected cells before de novo synthesis of viral proteins, which was also observed for CTLs targeting a Nef epitope. This very early clearance of infected cells depended on virus inoculum, and the required inoculum varied by epitope. These results suggest that whereas Gag-specific CTLs are more likely to recognize infected cells before Nef-mediated HLA-I down-regulation, this varies depending on the specific epitope and virus inoculum. Reduced susceptibility to Nef therefore may contribute to the overall association of Gag-specific CTL responses to better immune control if a sufficient multiplicity of infection is attained in vivo, but this property is not unique to Gag.


Sign in / Sign up

Export Citation Format

Share Document